Sign up
Pharma Capital
Market: NASDAQ
Sector: Pharma & Biotech
Market Cap: $218.59M

AcelRx Pharmaceuticals is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients.

AcelRx Pharmaceuticals

Interactive graph

col 3
col 4
col 5
col 6

AcelRx Pharmaceuticals Related Media

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.